Evaluación de la actividad mucolítica de los mucílagos presentes en los extractos acuosos de Malva sylvestris y Malva pseudolavatera
Fecha
2019
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Químicas
Resumen
La población mundial utiliza la medicina tradicional y gran parte de los tratamientos son utilizados para tratar o prevenir enfermedades respiratorias, como es el caso de Malva sylvestris que posee como principio activo mucílagos en sus flores y hojas. Debido a la presencia de dicha actividad farmacológica como es la mucolítica y a la falta de evidencia científica para Malva pseudolavatera se lleva a cabo la línea de investigación en el presente estudio como es la de evaluar la actividad mucolítica de los mucílagos de los extractos acuosos de Malva sylvestris y Malva pseudolavatera, mediante el uso del método del rojo fenol, en animales de experimentación. Así se conformaron 9 grupos con 7 animales cada uno, identificados con letras de la A hasta la I, siendo el Grupo A Control (normal), B Control (-); y reflejando los siguientes porcentajes de actividad mucolítica: Grupo C Control (+) Bromhexina (100,84%); Grupo D Malva pseudolavatera 250 mg (97,42%); Grupo E Malva pseudolavatera 500 mg (109,56%); Grupo F Malva pseudolavatera 1000 mg (148,63%); Grupo G Malva sylvestris 250 mg (82,73%); Grupo H Malva sylvestris 500 mg (102,64%); Grupo I Malva sylvestris 1000 mg (122,78%). Se logra evidenciar los porcentajes más altos en las dosis mayores, por lo que existe una relación directamente proporcional, dosis – respuesta; a mayor dosis mayor efecto; presentando mejor porcentaje de eficacia tanto Malva pseudolavatera como Malva sylvestris en las dosis de 500 y 1000 mg/kg frente al fármaco de referencia.
The world population uses traditional medicine and a large part of the treatments are used to treat or prevent respiratory diseases, as is the case of Malva sylvestris, which has mucilages in its flowers and leaves as its active principle. Due to the presence of this kind of pharmacological activity such as mucolytics and the lack of scientific evidence for Malva pseudolavatera, the research line is carried out in the present study, such as evaluating the mucolytic activity of the mucilage of the aqueous extracts of Malva sylvestris and Malva pseudolavatera, by using the phenol red method, in experimental animals. Thus 9 groups were formed with 7 animals each, identified with letters from A to I, with Group A Control (normal), B Control (-); and reflecting the following percentages of mucolytic activity: Group C Control (+) Bromhexine (100,84%); Group D Malva pseudolavatera 250 mg (97,42%); Group E Malva pseudolavatera 500 mg (109,56%); Group F Malva pseudolavatera 1000 mg (148,63%); Group G Malva sylvestris 250 mg (82,73%); Group H Malva sylvestris 500 mg (102,64%); Group I Malva sylvestris 1000 mg (122,78%). It is possible to show evidence of highest percentages in the higher doses, so there is a directly proportional relationship dose - response; higher doses, the greater effect, having better efficacy percentage both Malva pseudolavatera and Malva sylvestris at doses of 500 and 1000 mg/kg compared to the reference drug.
The world population uses traditional medicine and a large part of the treatments are used to treat or prevent respiratory diseases, as is the case of Malva sylvestris, which has mucilages in its flowers and leaves as its active principle. Due to the presence of this kind of pharmacological activity such as mucolytics and the lack of scientific evidence for Malva pseudolavatera, the research line is carried out in the present study, such as evaluating the mucolytic activity of the mucilage of the aqueous extracts of Malva sylvestris and Malva pseudolavatera, by using the phenol red method, in experimental animals. Thus 9 groups were formed with 7 animals each, identified with letters from A to I, with Group A Control (normal), B Control (-); and reflecting the following percentages of mucolytic activity: Group C Control (+) Bromhexine (100,84%); Group D Malva pseudolavatera 250 mg (97,42%); Group E Malva pseudolavatera 500 mg (109,56%); Group F Malva pseudolavatera 1000 mg (148,63%); Group G Malva sylvestris 250 mg (82,73%); Group H Malva sylvestris 500 mg (102,64%); Group I Malva sylvestris 1000 mg (122,78%). It is possible to show evidence of highest percentages in the higher doses, so there is a directly proportional relationship dose - response; higher doses, the greater effect, having better efficacy percentage both Malva pseudolavatera and Malva sylvestris at doses of 500 and 1000 mg/kg compared to the reference drug.
Descripción
Pdf
Palabras clave
PORCENTAJE, BROMHEXINA, ACTIVIDAD MUCOLÍTICA, MUCÍLAGOS, MALVA SYLVESTRIS